PD-184352 (Pfizer) was the first MEK inhibitor to enter clinical trials and it demonstrated inhibition of activated ERK and anti-tumor activity in patients [75]; however, subsequent multicenter, phase II studies with patients with diverse solid tumors did not demonstrate encouraging results [75]. This evidence concerns the gene MAP2K7 and neoplasm.